Overview

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
Phase:
Phase 2
Details
Lead Sponsor:
NanOlogy, LLC
Collaborator:
US Biotest, Inc.
Treatments:
Paclitaxel